A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration

This research project is designed to investigate a new medication, RBS-001, as a potential treatment for wet age-related macular degeneration (wet AMD). Wet AMD is a common eye condition that affects the macula, the part of your eye responsible for sharp, central vision, which you use for tasks like reading and recognising faces. In wet AMD, unwanted blood vessels grow under the macula, leaking fluid and blood, which can distort vision and lead to blind spots.

The main goal of this study is to compare RBS-001 with Eylea, a medication currently used to treat wet AMD. We want to see if RBS-001 is as effective, or even more effective, at improving and preserving your eyesight. We'll also be carefully monitoring how safe the new medication is and whether participants experience any side effects. This is a 'Phase 3' study, which means it’s a later stage of research involving a larger number of people, and the results from studies like this are very important for deciding if a new medicine should be approved for general use.

Throughout the study, we will be regularly checking your vision using a standard eye chart. We'll also use special eye scans, like OCT (Optical Coherence Tomography) and FA (Fluorescein Angiography), to look at the back of your eye, monitoring things like fluid build-up and the abnormal blood vessels. All these tests help us understand how well the treatments are working and track any changes in your eye health.